Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality.
about
Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes.Safety of Antiplatelet Agents: Analysis of 'Real-World' Data from the Italian National Pharmacovigilance Network.Bayesian assessment of adverse drug reactions.Agranulocytosis and hepatic toxicity with ticlopidine therapy: a case report
P2860
Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality.
@ast
Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality.
@en
Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality.
@nl
type
label
Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality.
@ast
Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality.
@en
Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality.
@nl
prefLabel
Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality.
@ast
Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality.
@en
Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality.
@nl
P2093
P2860
P1476
Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality
@en
P2093
C M Angelo
F L Paradiso-Hardy
K L Lanctôt
P2860
P304
P407
P577
2000-11-01T00:00:00Z